Clinical Trials List
2019-12-01 - 2026-10-31
Phase I/II
Recruiting2
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
TCM BIOTECH INTERNATIONAL CORP.
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 李宣書 Division of General Internal Medicine
- 廖思涵 Division of General Internal Medicine
- Ming-Chih Ho Division of General Internal Medicine
- JA-DER LIANG Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
0 participants
